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Summary 
Approximately 35 % of the mouse genes are indispensable for 
life, thus, global knock-out (KO) of those genes may result in 
embryonic or early postnatal lethality due to developmental 
abnormalities. Several KO mouse lines are valuable human 
disease models, but viable homozygous mutant mice are 
frequently required to mirror most symptoms of a human 
disease. The site-specific gene editing systems, the transcription 
activator-like effector nucleases (TALENs), Zinc-finger nucleases 
(ZFNs) and the clustered regularly interspaced short palindrome 
repeat-associated Cas9 nuclease (CRISPR/Cas9) made the 
generation of KO mice more efficient than before, but the 
homozygous lethality is still an undesired side-effect in case of 
many genes. The literature search was conducted using PubMed 
and Web of Science databases until June 30th, 2020. The 
following terms were combined to find relevant studies: 
“lethality”, “mice”, “knock-out”, “deficient”, “embryonic”, 
“perinatal”, “rescue”. Additional manual search was also 
performed to find the related human diseases in the Online 
Mendelian Inheritance in Man (OMIM) database and to check the 
citations of the selected studies for rescuing methods. In this 
review, the possible solutions for rescuing human disease-
relevant homozygous KO mice lethal phenotypes were 
summarized. 
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Introduction 
Generating KO animals gives the opportunity to 
observe a whole organism if a gene is disrupted and it 
provides an answer to the origin and course of the 
appearance of various diseases. The production of these 
animal models is efficient enough nowadays although, 
a long journey led to the techniques of developing models 
that are now easy to produce. 
The first two methods to generate KO mice were 
gene trapping (Gossler et al. 1989) and gene targeting 
(Mansour et al. 1988). Both methods required embryonic 
stem cells (ESCs), produced chimeric mice and were 
neither cost nor time effective. Transposon systems were 
also practical tools to disrupt genes in mice (Dupuy et al. 
2001), however, transposon-based approaches proved to be 
very effective in creating transgenic animals later (Garrels 
et al. 2011, Katter et al. 2013). Site-specific endonucleases, 
TALENs, ZFNs and CRISPR/Cas9 are the latest members 
of the gene-editing toolbox. TALENs and ZFNs require 
engineered proteins, while CRISPR/Cas9 is RNA-guided. 
CRISPR/Cas9 gene editing requires the Cas9 mRNA or 
protein and the single guide RNA (sgRNA), which consists 
of the trans-activating RNA and CRISPR RNA. All of the 
aforementioned endonucleases induce site-specific double-
strand breaks (DSBs) in the genome, which are usually 
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repaired by either non-homologous end joining (NHEJ) or 
homology-directed repair (HDR). NHEJ is predominant 
during the G1 phase, while HDR is active in S and 
G2 phases (Zaboikin et al. 2017). Both HDR and NHEJ 
can evoke small indels and point mutations, but HDR may 
also generate large insertions in the targeted genes if 
homologous template DNA is available. CRISPR/Cas9 
system became the most efficient and broad spread tool for 
creating KO laboratory animals, e.g. mice (Wang et al. 
2013), rats (Yoshimi et al. 2014), rabbits (Yang et al. 
2014), etc., and a less expensive alternative of the 
previously described TALEN and ZFN applications 
(Ceasar et al. 2016). The widely accepted method of 
disrupt genes in animals with site-specific endonucleases is 
the microinjection of those gene-editing constructs into 
once-cell stage embryos. 
Systemic phenotyping data, which were provided 
by International Mouse Phenotyping Consortium revealed 
that approximately 35 % of the mouse genes were essential 
for viability (Brown and Moore 2012). Several reports, 
along with recent studies claimed that heterozygous mutant 
mice did not develop the symptoms of a human disease 
and the homozygous KO mice were not viable. 
The novel strategies to overcome KO mouse 
embryonic and postnatal lethality are described in detail in 
the following sections and Table 1, along with the related 
human diseases. 
 
Mosaic inactivation of the target gene for 
rescuing the KO lethal phenotype 
 
The generation of chimeric mice with gene 
targeting using ESCs was successful to establish KO mice 
(Crosby et al. 1998, Lindahl et al. 1998), but this method 
was laborious and expensive. 
Mutations in the serine protease inhibitor Kazal-
type 5 (SPINK5) gene were associated with Netherton 
syndrome, an autosomal recessive disorder which caused 
dermatitis, severe dehydration due to the malfunctioning 
epidermal barrier (OMIM 256500) (Chavanas et al. 2000). 
Spink5 KO (Spink5−/−) mice were created by insertional 
mutagenesis (Yang et al. 2004) for studying Netherton 
syndrome, but Spink5−/− mice died within few hours after 
birth. Mosaic inactivation of the Spink5 gene using 
TALEN resulted in viable Spink5−/− KO mice,  
an appropriate animal model for human Netherton 
syndrome (Kasparek et al. 2016). Mosaicism could occur 
normally if the gene-editing endonucleases activated after 
the one-cell embryonic stage. One-cell stage embryos were 
microinjected with different concentrations of TALEN 
mRNA. Mild skin phenotype was observed in 8 % and 
17 % of the pups from the higher concentrations of 
TALEN mRNA-groups (Kasparek et al. 2016). 
Mutations of cytotoxic T-lymphocyte antigen-4 
(CTLA-4) gene were identified as potential basis of 
autoimmune lymphoproliferative syndrome 5 (ALPS 5, 
OMIM 616100 (Schubert et al. 2014)). Loss of Ctla-4 
caused premature lethality in case of gene-targeted  
Ctla-4−/− KO mice (Waterhouse et al. 1995). This issue 
remained unsolved until the invention of two-cell 
microinjection (Wang et al. 2017). This method was further 
developed to create KO mosaic mice with lethal mutations 
by one-step microinjection of the CRISPR/Cas9 reagents 
into one blastomere of two-cell stage embryos. Among 
others, a premature lethal phenotype, which was caused by 
Ctla-4−/− mutation was rescued and Ctla-4−/− KO mice 
survived for more than five months (Wu et al. 2019). 
 
Disruption of other genes involved in the 
affected pathway 
 
In the first two reports, embryonic lethal 
phenotype caused by the deletion of Mouse double minute 
2 homolog (Mdm2) was rescued by the disruption of p53 
(Jones et al. 1995, Luna et al. 1995). Mdm2−/−p53−/− 
double KO mice became a valuable model for studying 
human tumorigenesis (OMIM 614401, (Xiao et al. 1995)). 
SPINK5 gene encodes lympho-epithelial Kazal-
type related inhibitor (LEKTI), an inhibitor of kallikrein-
related peptidases 5, 7 (KLK5, 7) and other serine 
proteases in the epidermis (Chavanas et al. 2000). In 
newborn Spink5−/− mice, elevated activation of the pro-
kallikrein-cascade in the epidermis and stratum corneum 
was observed earlier (Sales et al. 2010). Taking advantage 
of this pathway, Klk5+/− mouse line was generated, crossed 
with Spink5+/− mice to create Klk5−/−Spink5−/− double 
KO mice for modeling Netherton syndrome. The loss of 
Klk5 rescued the neonatal lethal phenotype, which was 
evoked by Spink5 deficiency but the life span of 
Klk5−/−Spink5−/− mice was not as long as wild type (wt) 
littermates (Furio et al. 2015). Klk5-7 were disrupted by 
gene-targeting and TALEN, respectively, then 
Klk5−/−Klk7−/− double KO mice mated with Spink5+/− 
mice. Triple KO mice developed as normally as wt mice 
and fatal dehydration or severe defects of the epidermal 
barrier were not detected (Kasparek et al. 2017). In a very 
recent study, the deletion of Klk5 and Camp (Cathelicidin 
antimicrobial peptide) were also sufficient to alleviate the 
severe symptoms evoked by the disruption of Spink5 in 
mice (Zingkou et al. 2020). 
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Table 1. The novel strategies to overcome KO mouse embryonic and postnatal lethality. 
 




KO mice with lethal 
phenotype 
Methods for phenotype rescuing 
ALPS 5, 616100 CTLA-4 
Premature lethality 
(Waterhouse et al. 1995) 
Two-cell microinjection, highly 
effective, CRISPR/Cas9 (Wu et al. 
2019). 
Accelerated tumor formation, 
614401 
MDM2 
Embryonic lethality (Jones 
et al. 1995, Luna et al. 
1995) 
Disruption of p53 (Jones et al. 1995, 
Luna et al. 1995) 
MODY-2, 125851 GCK 
Embryonic lethality 
(Bali et al. 1995) 
Tissue-specific KO mice, modest 
success (Postic et al. 1999, Terauchi 
et al. 1995, Zhang et al. 2004) 
Homozygous mutant rabbits 






(Mounkes et al. 2003, 
Sullivan et al. 1999) 
KO rabbits, CRISPR/Cas9, modest 





(Yang et al. 2004) 
Mosaic mice, TALEN (Kasparek et 
al. 2016); 
Disruption of Klk 5 (Furio et al. 
2015); 
Klk5 and Klk7 (Kasparek et al. 2017); 






(Yamamoto et al. 1998) 
Tetraploid complementation 
(Yamamoto et al. 1998), lentiviral 
gene transfer (Okada et al. 2007) 
SCAR26, 617633 XRCC1 
Embryonic lethality 
(Tebbs et al. 1999) 
Transgene complementation (Tebbs 





(Ohmuraya et al. 2005) 
Spink3−/−; XXSPINK1 knock-in mice 
















(Thiel et al. 2006) 
 
 
(DeRossi et al. 2006) 
 
(Balakrishnan et al. 2019) 
Mannose drinking, modest success 
(Schneider et al. 2011), (Chan et al. 
2016) 
Hypomorphic mice (Sharma et al. 
2014) 
No solutions yet, galactose drinking 
was inefficient (Balakrishnan et al. 
2019) 
Premature ovarian failure, 
147380 
INHA (Matzuk et al. 1992) 
Bigenic mice, GeneSwitch method 
(Pierson et al. 2000) 
 
Abbrevations: ALPS 5: autoimmune lymphoproliferative syndrome 5, CTLA-4: cytotoxic T-lymphocyte antigen-4, MDM2: mouse double 
minute 2 homolog, MODY-2: maturity-onset diabetes of the young 2, GCK: glu cokinase, Klk: Kallikrein-related peptidase, HPGS: 
Hutchinson-Gilford progeria syndrome, EDMD: Emery-Dreifuss muscular dystrophy, LMNA: nuclear lamin A, SPINK: serine protease 
inhibitor Kazal-type, Camp: Cathelicidin antimicrobial peptide, ERF: ETS proto-oncogene 2 (ETS2) repressor factor, SCAR26: 
spinocerebellar ataxia-26, XRCC1: x-ray cross-complementing 1, CDG: congenital disorder of glycosylation, PMM2: 
phosphomannomutase 2, MPI: phosphomannose isomerase, PGM1: phosphoglucomutase 1, INHA: inhibin alpha. 
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Inducible KO models 
 
Conditional KO technologies were developed for 
temporal gene expression in mice; e.g. the inducible 
KO (iKO) method, in which the target gene could be 
switch on and off with doxycycline treatment (Zeng et al. 
2008); the mifepristone-inducible GeneSwitch approach 
(Wang et al. 1994), etc. 
Polymorphism in INHIBIN alpha (INHA) 
promoter was associated with premature ovarian failure 
(OMIM: 147380 (Harris et al. 2005)). Inha deficient mice 
(Inha−/−) died 12-17 weeks after birth due to gonadal 
tumors (Froguel et al. 1992). GeneSwitch approach was 
successfully applied to rescue the lethal phenotype which 
was evoked by the disruption of Inha in mice. Bigenic 
mice were produced by crossing of transgenic mice with 
liver-specific mifepristone-induced chimeric nuclear 
receptor (GLVP) and transgenic target mice containing 
a GVLP-responsive promoter upstream of polio-virus 
internal ribosome entry site-linked sequences coding of 
inhibin A (Pierson et al. 2000). 
 
Overcome perinatal lethality by integration 
of the target gene into the X-chromosome 
 
SPINK1 mutations may lead to various types of 
chronic pancreatitis (OMIM 167800, 608189) (Witt et al. 
2000)). Spink3, the mouse homologue of human SPINK1 
was disrupted by gene targeting, but Spink3 
KO (Spink3−/−) mice died within two weeks after birth 
due to the improper inactivation of intrapancreatic 
trypsinogen and Spink3+/− mice did not develop this 
disorder (Ohmuraya et al. 2005). For rescuing the lethal 
phenotype, human SPINK1 minigene was integrated into 
the X-chromosome. Mosaic expression of the SPINK1 
mRNA was achieved by the random inactivation of the  
X-chromosome (Sakata et al. 2016). Spink3+/− and 
XXSPINK1 knock-in mice were mated to generate 
Spink3−/−; XXSPINK1 mice. Spink3−/−; XXSPINK1 mice also 
showed the symptoms of chronic pancreatitis such as loss 
of acinar cells, intralobular fibrosis but reached sexual 
maturity and therefore proved to be a valuable model for 
the human disorder (Sakata et al. 2016). 
 
Tetraploid complementation assay 
 
Placental defects induced by gene deletions are 
frequently responsible for embryonic lethality in mice 
(for more details, see review (Rossant and Cross, 2001)). 
ETS proto-oncogene 2 (ETS2) repressor factor (ERF) 
mutations evoke craniosynostosis (Twigg et al. 2013) and 
Chitayat syndrome (OMIM 611888 (Chitayat et al. 
1993)). Ets proto-oncogene 2 (Ets2) was disrupted by 
gene targeting, but Ets2−/− embryos were arrested at 
day 8 (Yamamoto et al. 1998). Tetraploid 
complementation assay could be a valuable method 
where a tetraploid embryo (morula or blastocyst stage) is 
aggregated with diploid ESCs. The aggregation results  
a normally developed fetus, which is exclusively derived 
from the ESCs, while the extra-embryonic tissues are 
completely derived from the tetraploid cells.  
Ets2-deficient embryos were efficiently rescued by 
tetraploid complementation (Yamamoto et al. 1998). 
 
Lethal phenotype rescuing by transgene-
complementation 
 
X-ray cross-complementing 1 (XRCC1) protein 
is an indispensable part of the DNA single-strand break 
repair system. (Whitehouse et al. 2001). Spinocerebellar 
ataxia was evoked by mutations in the XRCC1 in human 
patients (Hoch et al. 2017). Xrcc1+/− mice were 
developed by gene targeting earlier to study the functions 
of that gene, but Xrcc1−/− mouse embryos aborted 
between day 6 and 8, thus, the function of that protein in 
adult mice was not possible to assess (Tebbs et al. 1999). 
Xrcc1 minigene was integrated into the mouse 
genome to rescue the phenotype. Although the Xrcc1 
mRNA level was only 10 % in transgenic mice compared 
with wt littermates, this reduced Xrcc1 mRNA level was 
enough the overcome embryonic lethality (Tebbs et al. 
2003). Lentiviral gene transfer was also effective in 
rescuing the lethal phenotype evoked by Ets2, Mitogen-
activated protein kinase (Mapk) 14 and Mapk1 deficiency 
in mice (Okada et al. 2007). 
 
Tissue-specific deletion of the target gene 
 
Mutations in the glucokinase gene (GCK) were 
associated with maturity-onset diabetes of the young 2 
(MODY-2, OMIM 125851, (Froguel et al. 1992)). 
Heterozygous Glucokinase (Gck+/−) mutant mice were 
generated by gene targeting as a MODY-2 animal model, 
but their plasma glucose and insulin levels were similar 
compared to Gck+/+ mice. Unfortunately, the complete 
lack of the enzyme resulted in lethality at embryonic day 
9.5 (Bali et al. 1995). Numerous mouse lines were 
created with liver or pancreatic β-cell-specific deletion of 
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the Gck gene to prevent embryonic lethality. Pancreatic-
specific Gck−/− mice died seven days after birth due to 
glycosuria and severe dehydration, while Gck+/− mice 
showed only mild diabetes (Postic et al. 1999, Terauchi 
et al. 1995). Liver-specific Gck−/− mice were created 
using Cre/Lox technology. The lack of hepatic Gck 
rescued the lethal phenotype, which was observed in 
global and pancreatic Gck−/− mice. Hepatic Gck−/− mice 
showed mild hyperglycemia and impaired insulin 
secretion. (Postic et al. 1999) These data were confirmed 




Several attempts were made to create adequate 
KO mouse models for different types of congenital 
disorder of glycosylation (CDG), e.g. CDG-Ia, OMIM 
212065 (Dupre et al. 2001); CDG-It, OMIM 614921 
(Ondruskova et al. 2014), CDG-Ib, OMIM 602579 
(Niehues et al. 1998), etc. Phosphomannose isomerase 
KO (Mpi−/−) mice died during embryonic development 
due to mannose 6-phosphate accumulation (DeRossi  
et al. 2006). Phosphomannomutase 2-deficient 
(Pmm2−/−) mouse line, a promising model for human 
CDG-Ia could not be established due to embryonic 
lethality (Thiel et al. 2006). Phosphoglucomutase 2 KO 
(Pgm2−/−) newborn mice were not detected after  
ten Pgm2+/−x Pgm2+/− crossings, and the Pgm2+/− mice 
had different glycosylation pattern compared to human 
patients with CDG-It (Balakrishnan et al. 2019). Prenatal 
mannose supplementation was utilized to overcome 
embryonic lethality of Pmm2−/− mice (Schneider et al. 
2011). Pmm2R137H/F118l compound heterozygous mouse 
line was created as an analog of the human CDG-Ia-
associated Pmm2R141H/F122L genotype. 9 mg/ml mannose 
were added to the drinking water of female Pmm2+/F118L 
before mating with Pmm2R137H/+ males and during 
pregnancy. This mannose-drinking protocol proved to be 
an efficient method to rescue lethality of Pmm2R137H/F118L 
(Schneider et al. 2011) and Pmm2F115L/F115L embryos 
(Chan et al. 2016), but not in case of Pmm2R137H/F118L 
mice, a model of the human CDG-Ia-related 
Pmm2R141H/F119L genotype (Chan et al. 2016). Strikingly, 
mannose treatment worsened embryonic lethality in the 
Phosphomannose isomerase KO (Mpi−/−) (DeRossi et al. 
2006) and Mpi hypomorphic mouse line, models of 
human CDG-Ib (Sharma et al. 2014). 
Unfortunately, drinking galactose (9 mg/ml) to 
pregnant Pgm2+/− mice, model of human CDG-It was not 
effective to induce survival of Pgm2−/− mice beyond 
embryonic development (Balakrishnan et al. 2019). 
 
Disruption of the target gene in rabbits 
 
If a KO mouse line is not able to develop the 
symptoms of a human disease, using other laboratory 
animals could be a practical option. 
GCK mutant rabbits were generated using the 
CRISPR/Cas9 system for modeling MODY-2 (Froguel  
et al. 1992). Both GCK+/− and GCK−/− rabbits with 
frameshift mutations (GCK-FS) died before sexual 
maturity. Heterozygous GCK mutant rabbits with non-
frameshift mutation (GCK-NFS) were viable, fertile, 
hence homozygous GCK-NFS rabbit line could be 
established. Homozygous GCK-NFS rabbits had similar 
symptoms as human MODY-2 patients (elevated fasting 
serum glucose, decreased serum insulin, glycosuria), thus 
may serve as a valuable model for human MODY-2 
(Song et al. 2020). 
Nuclear lamin A gene (LMNA) mutations were 
related to numerous human diseases, e.g. lipodystrophy 
(OMIM 151660, (Shackleton et al. 2000)), Hutchinson-
Gilford progeria syndrome (HGPS, OMIM 176670, (Cao 
and Hegele, 2003)), Emery-Dreifuss muscular dystrophy 
(EDMD, OMIM 181350, (Bonne et al. 1999)). Lmna−/− 
KO mice showed similar symptoms as human EDMD 
and HPGS patients but died at 8 and 4 weeks of age, 
respectively. Lmna+/− mutant mice developed as normal 
as wt mice, but human-EDMD or HPGS-like symptoms 
were not observed (Mounkes et al. 2003, Sullivan et al. 
1999). LMNA−/− KO rabbits created by CRISPR/Cas9 
system as a model for human LMNA mutations-related 
disorders (Sui et al. 2019). LMNA−/− KO rabbits had 
dilated cardiomyopathy, lipodystrophy and premature 
aging, reflecting human EDMD, lipodystrophy and 
HPGS. However, LMNA−/− rabbits had shorter life span 
compared with Lmna−/− mice (Sui et al. 2019), indicating 
a limited application of the LMNA−/− rabbit line for 




Embryonic and postnatal lethality limited the 
translational value of many KO mouse lines in the past 
three decades. The most promising method to rescue  
a lethal phenotype is the creation of mosaic mice by 
TALEN or CRISPR/Cas9 system. This one-step 
technique can be performed on either one-cell or two-cell 
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stage embryos, but two-cell microinjection is more 
efficient. The disruption of other genes is a convincing 
method as well but it requires the development or 
purchasing of further KO mouse lines and also needs 
several crossings to establish double or triple KO mice. 
Mannose supplementation was utilized in several KO 
mouse lines, which were developed for studying various 
types of human CDG. The success of this approach was 
restricted to Pmm2R137H/F118L and Pmm2F115L/F115L 
genotypes, modeling human CDG-Ia. KO rabbits may 
provide an alternative of KO mice to overcome 
embryonic or postnatal lethality in the future, but the 
establishment and characterization of a KO rabbit line 
could be expensive and time consuming. 
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